Breo Ellipta 200 ug/1

Breo Ellipta 200 ug/1 is a combination inhaler containing fluticasone furoate and vilanterol trifenatate. It is designed for respiratory use and is commonly used for managing asthma and chronic obstructive pulmonary disease (COPD). This powder inhaler is manufactured by GlaxoSmithKline LLC.

Breo Ellipta 200 ug/1 is primarily used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It combines an inhaled corticosteroid and a long-acting beta-agonist to help control symptoms such as wheezing, shortness of breath, and coughing. This medication is often prescribed to improve lung function and reduce the frequency of asthma or COPD exacerbations.

Common effects of Breo Ellipta 200 ug/1 may include throat irritation, headache, and hoarseness. Some users might experience tremors, nausea, or an increased heart rate. These effects can vary from person to person and are not experienced by everyone who uses the medication.

Breo Ellipta 200 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as heart disease or diabetes, should discuss the use of this medication with their healthcare provider. Always store the inhaler in a clean, dry place and keep it out of reach of children.

Breo Ellipta 200 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare professional.